LAVAL, Quebec / Jun 21, 2023 / Business Wire / Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 20, 2023. The detailed results of the votes received by proxy are as follows:
Election of Directors
Director Nominees | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
FOR | WITHHELD | FOR | WITHHELD | |
Daniel N. Chicoine | 4,113,511 | 91,743 | 97.8% | 2.2% |
Anthony E. Dobranowski | 3,549,815 | 655,439 | 84.4% | 15.6% |
John C. London | 3,550,494 | 654,760 | 84.4% | 15.6% |
Deborah Shannon-Trudeau | 4,115,644 | 89,610 | 97.9% | 2.1% |
Serge Verreault | 3,550,534 | 654,720 | 84.4% | 15.6% |
Appointment of External Auditors
Outcome | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
FOR | WITHHELD | FOR | WITHHELD | |
Ernst & Young LLP reappointed | 4,965,906 | 47,466 | 99.1% | 0.9% |
Consideration of a Special Resolution Approving a Change of the Municipality of Crescita’s Registered Office
Outcome | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||
FOR | AGAINST | FOR | AGAINST | |
Change of municipality approved | 4,181,460 | 23,794 | 99.4% | 0.6% |
About Crescita Therapeutics Inc.
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and early to commercial stage prescription products. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For further details, visit www.crescitatherapeutics.com.
| Last Trade: | C$0.60 |
| Daily Volume: | 0 |
| Market Cap: | C$11.630M |
August 07, 2024 July 22, 2024 July 19, 2024 July 17, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
